Vedanta, PureTech’s microbiome startup, to cut staff after study setback
Written by
BioPharma Dive
Published
0
comments
0
min
The result marks the latest failure for a microbiome therapy in inflammatory bowel disease, which has long been a top target of Vedanta and other companies like it.